SEC Form 4 · accession 0001079973-26-000939
Starling Oncology, Inc. · STLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Stolper
Director
Period of report
Jul 7, 2026
Accepted (ET)
Jul 9, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001799191
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 7, 2026 | A | 25,833 | $0.00 | A | 25,833 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents RSU award that was fully vested upon grant.